Bruker Daltonics Introduces New MALDI Molecular Imager(TM) for In-Vitro Imaging of Protein Biomarkers in Tissue Sections and Ce
March 10 2006 - 7:00AM
Business Wire
Bruker Daltonics today announces its novel MALDI Molecular
Imager(TM), a system for in-vitro imaging of peptide and protein
biomarker distributions in tissue sections and cell clusters, for
example from tumor regions. The MALDI Molecular Imager addresses
the need for high-sensitivity imaging of the spatial distribution
of protein biomarkers in biological, pathology and other clinical
research (for research use only). The MALDI Molecular Imager uses
an easy-to-use autoFlex(TM) MALDI-TOF mass spectrometer equipped
with proprietary smartbeam(TM) laser technology for high-throughput
MALDI Imaging. The MALDI Molecular Imager also incorporates
powerful flexImaging(TM) visualization and image processing
software, and further expands Bruker Daltonics' leading
CLINPROT(TM) product line for clinical proteomics and protein
biomarker analysis. The novel and unique MALDI Molecular Imager can
be applied whenever tissue sections are used to evaluate cellular
histology and to monitor the spatial distribution of biomarkers,
e.g. in pathology, morphology, oncology or neurology, and many
other clinical research fields. In addition, the MALDI Molecular
Imager can be of great value in pharmacology, for example for
peptide and protein tissue characterization in transgenic animal
models, as well as in basic biological research. Prof. Richard M.
Caprioli, Director, Mass Spectrometry Research Center at the
Vanderbilt University Medical Center (Nashville, TN) and first
customer of the MALDI Molecular Imager, commented: "Biomarker
discovery will benefit enormously from the direct analysis of
tissue sections by MALDI-MS. Gaining knowledge about the spatial
localization of proteins and compounds in tissue will also provide
invaluable knowledge to drug candidate research and chemical
compound monitoring in animal and plant tissue." Dr. Isabelle
Fournier, Director of MALDI Imaging in the Neuroimmunology
Laboratory of Prof. Michel Salzet at the University of Lille
(France), pointed out: "The MALDI Molecular Imager is an important
tool for histological research projects. In comparison to
immuno-histochemical techniques, it is of special interest that
there is neither a need for labeling of biomarkers, nor for the use
of antibodies. Moreover, direct profiling of cancer regions
identified in tissue biopsies in many cases allows for a sub-typing
of tumors, thus giving clinicians additional information for
diagnosis and therapy decisions." Frank Laukien, Ph.D., President
and CEO of Bruker Daltonics, stated: "The dedicated MALDI Molecular
Imager for in-vitro protein biomarker imaging is a powerful new
tool for molecular imaging. We believe that our proprietary
smartbeam technology and advanced flexImaging software make this a
user-friendly system for many clinical research and biological
laboratories that typically would not use mass spectrometry.
Together with our collaborators, we are looking forward to bringing
this exciting new molecular imaging modality to new customer groups
who can benefit from its unique capabilities." Pittcon 2006, the
57th Pittsburgh Conference and Exposition on Analytical Chemistry
and Applied Spectroscopy, will be held March 13-16 in Orlando,
Florida in the Orange County Convention Center. The MALDI Molecular
Imager will be exhibited at the Bruker booth #3155. ABOUT BRUKER
BIOSCIENCES (NASDAQ: BRKR) Bruker BioSciences Corporation,
headquartered in Billerica, Massachusetts, is the publicly traded
parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker
AXS is a leading developer and provider of life science, materials
research and industrial X-ray analysis tools. Bruker Daltonics is a
leading developer and provider of innovative life science tools
based on mass spectrometry. Bruker Daltonics also offers a broad
line of nuclear, biological and chemical (NBC) detection products
for defense and homeland security. For more information, please
visit www.bruker-biosciences.com CAUTIONARY STATEMENT Any
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of
conditions, technological approaches, product development, market
acceptance, cost and pricing of the Company's products, exposure to
currency fluctuations, changes in governmental regulations, capital
spending and government funding policies, FDA and other regulatory
approvals to the extent applicable, competition, the intellectual
property of others, patent protection and litigation. These and
other factors are identified and described in more detail in our
filings with the SEC, including, without limitation, our respective
annual reports on Form 10-K, our most recent quarterly reports on
Form 10-Q, and our current reports on Form 8-K. We disclaim any
intent or obligation to update these forward-looking statements.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024